By: Radha McLean
Advanced Tissue Sciences Inc. of La Jolla, California, and Smith & Nephew PLC, of London, England, announced the FDA approval of Dermagraft, a treatment for foot ulcers resulting from diabetic neuropathy. Advanced Tissue Sciences is the first company in the United States to receive FDA approval for a skin treatment that is engineered from human cells.
Dermagraft is a skin substitute that contains active, living cells. It comes in the form of a thin sheet of human tissue that must be applied by a clinician. Once the foot wound is cleaned, the sheet of tissue is placed on the wound, measured to fit the area and cut from the sheet. Then, the tissue is implanted into the wound by a doctor.
For more information on Dermagraft, call Smith & Nephew’s Wound Management Division at (800) 876-1261.